Early treatment of idiopathic Parkinson's disease with dopaminergic agonist piribedil in monotherapy. A two-year randomised, parallel, placebo-controlled study in idiopathic Parkinsonian de novo patients
Not Applicable
Completed
- Conditions
- Parkinson's diseaseNervous System Diseases
- Registration Number
- ISRCTN36646813
- Lead Sponsor
- Institut de Recherches Internationales Servier (France)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Out-patients between 30 to 77 years old, with stage 1 to 3 (Hoehn and Yahr) and less than six weeks of previous L-dopa treatment, with less than 3 months of previous treatment by a dopaminergic agonist
Exclusion Criteria
1. Patients frequently falling according to unified Parkinson's disease rating scale (UPDRS) II and/or III
2. Prior experience of a dopaminergic complication
3. Prior neurosurgery for PD
4. Previous history of freezing
5. Suspected autosomal juvenile Parkinsonism
6. Atypical Parkinsonian symtoms caused by drugs, metabolic disorders or encephalitis
7. History of psychotic symptoms
8. Poor cognitive performance
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method